PMID- 28695347
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2193-8229 (Print)
IS  - 2193-6382 (Electronic)
IS  - 2193-6382 (Linking)
VI  - 6
IP  - 3
DP  - 2017 Sep
TI  - Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A 
      Retrospective Analysis of ATLAS and ATTAIN Studies.
PG  - 413-422
LID - 10.1007/s40121-017-0162-1 [doi]
AB  - INTRODUCTION: Concurrent Staphylococcus aureus bacteremia (SAB) worsens outcomes 
      and increases mortality in patients with complicated skin and skin structure 
      infections (cSSSI), hospital-acquired bacterial pneumonia, and 
      ventilator-associated bacterial pneumonia (HABP/VABP). These challenges highlight 
      the need for alternative treatments. Telavancin (TLV), a bactericidal 
      lipoglycopeptide with high in vitro potency, effectively treats patients with 
      cSSSI and HABP/VABP caused by Gram-positive pathogens, particularly S. aureus. 
      METHODS: This retrospective analysis evaluated patients from the Assessment of 
      Telavancin in Complicated Skin and Skin Structure Infections and Assessment of 
      Telavancin for Treatment of Hospital-Acquired Pneumonia studies with baseline, 
      concurrent SAB. Differences in the clinical cure rates at test-of-cure and safety 
      outcomes were compared for TLV vs vancomycin (VAN) treatment groups. RESULTS: A 
      total of 105 patients, 32 cSSSI and 73 HABP/VABP, had baseline, concurrent SAB. 
      The clinical cure rates for all-treated SAB patients in the cSSSI (TLV 57.1% and 
      VAN 54.5%) and HABP/VABP (TLV 54.3% and VAN 47.2%) groups were comparable. For 
      both types of infections, the safety profile of TLV and VAN showed similar 
      incidences of adverse events (AEs), serious AEs, or AEs leading to 
      discontinuation. One VAN-treated patient died in the cSSSI group, and there were 
      13 deaths in each treatment arm of the HABP/VABP group. CONCLUSION: This 
      retrospective analysis demonstrated that TLV is clinically comparable in both 
      efficacy and safety to VAN, and, therefore, may be an appropriate therapeutic 
      option for the treatment of patients with HABP/VABP or cSSSI and concurrent SAB. 
      Given the limited sample size in this subgroup, the interpretation of these 
      results is limited. FUNDING: Theravance Biopharma Antibiotics, Inc.
FAU - Wilson, Samuel E
AU  - Wilson SE
AD  - University of California, Irvine, CA, USA.
FAU - Graham, Donald R
AU  - Graham DR
AD  - Springfield Clinic, Springfield, IL, USA.
FAU - Wang, Whedy
AU  - Wang W
AD  - Theravance Biopharma US, Inc., South San Francisco, CA, USA.
FAU - Bruss, Jon B
AU  - Bruss JB
AD  - Theravance Biopharma US, Inc., South San Francisco, CA, USA.
FAU - Castaneda-Ruiz, Bibiana
AU  - Castaneda-Ruiz B
AD  - Theravance Biopharma US, Inc., South San Francisco, CA, USA. 
      BCastaneda@theravance.com.
LA  - eng
PT  - Journal Article
DEP - 20170710
PL  - New Zealand
TA  - Infect Dis Ther
JT  - Infectious diseases and therapy
JID - 101634499
PMC - PMC5595776
OTO - NOTNLM
OT  - Complicated skin and skin structure infection
OT  - Concurrent bacteremia
OT  - MRSA
OT  - Pneumonia
OT  - Staphylococcus aureus
OT  - Telavancin
OT  - Vancomycin
EDAT- 2017/07/12 06:00
MHDA- 2017/07/12 06:01
PMCR- 2017/07/10
CRDT- 2017/07/12 06:00
PHST- 2017/03/14 00:00 [received]
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2017/07/12 06:01 [medline]
PHST- 2017/07/12 06:00 [entrez]
PHST- 2017/07/10 00:00 [pmc-release]
AID - 10.1007/s40121-017-0162-1 [pii]
AID - 162 [pii]
AID - 10.1007/s40121-017-0162-1 [doi]
PST - ppublish
SO  - Infect Dis Ther. 2017 Sep;6(3):413-422. doi: 10.1007/s40121-017-0162-1. Epub 2017 
      Jul 10.